Banking on iPSC- Is it Doable and is it Worthwhile

Stem Cell Reviews and Reports

Volumn 11, Issue 1, 2015, Pages 1-10

  Solomon, Susan ^a   Pitossi, Fernando ^b   Rao, Mahendra S ^a  

^a New York Stem Cell Foundation Laboratory   (United States)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

cGMP; Consent; Embryonic stem cells; Induced pluripotent stem cells; Manufacturing; Markers

Indexed keywords

HLA ANTIGEN;

CYTOLOGY; GENETICS; HEALTH CARE FACILITY; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; PLURIPOTENT STEM CELL; PROCEDURES; STEM CELL TRANSPLANTATION;

BIOLOGICAL SPECIMEN BANKS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84923643825     PISSN: 26293269     EISSN: 26293277     Source Type: Journal    
DOI: 10.1007/s12015-014-9574-4     Document Type: Article

References (95)

1. Nishikawa, S., Goldstein, R. A., & Nierras, C. R. (2008). The promise of human induced pluripotent stem cells for research and therapy. Nature Reviews Molecular Cell Biology, 9, 725–729.
2. Okano, H., Nakamura, M., Yoshida, K., Okada, Y., Tsuji, O., et al. (2013). Steps toward safe cell therapy using induced pluripotent stem cells. Circulation Research, 112, 523–533.
3. Inoue, H., & Yamanaka, S. (2011). The use of induced pluripotent stem cells in drug development. Clinical Pharmacology & Therapeutics, 89 5, 655–661. doi:10.1038/clpt.2011.38.
4. Rao, M. (2013). iPSC crowdsourcing: a model for obtaining large panels of stem cell lines for screening. Cell Stem Cell, 13, 389–391.
5. Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., et al. (2013). Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell, 13, 382–384.
6. de Rham, C., & Jean, V. (2014). Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. Journal of Immunology Research Volume, 518135, 6.
7. Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient hla types. Cell Stem Cell, 11(2), 147–152.
8. http://advbiols.com/documents/BraveryAllogeneicCBstrategyAbstract31.pdf
9. http://stemcellassays.com/2014/09/challenges-commercialization-of-hla-typed-ips-cell-banks/
10. http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm150485.htm
11. Galea, I., Beckmann, I., & Perry, V. H. (2007). What is immune privilege (not)? Trends in Immunology, 28(1), 12–18.
12. Streilein, J. W., & Stein-Streilein, J. (2002). Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. International Reviews of Immunology, 21(2–3), 123–52.
13. Hong, S., & Van Kaer, L. (1999). Immune privilege: keeping an eye on natural killer T cells. The Journal of Experimental Medicine, 190(9), 1197–1200.
14. Freed C. R., Greene P. E., Breeze R. E., et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. New England Journal of Medicine, 344, 710–719.
15. Winkler C., Kirik D., Bjo rklund A. (2005). Cell transplantation in Parkinson’s disease: how can we make it work? Trends in Neurosciences, 28, 86–92.
16. Zenclussen A. C., Schumacher A., Zencluseen M. L., Wafula P., Volk H. D. (2007). Immunology of pregnancy: cellular mechanisms allowing fetal survival within the maternal uterus. Expert Reviews in Molecular Medicine, 9(10), 1–14.
17. Lobach, D. F., & Haynes, B. F. (1987). Ontogeny of the human thymus during fetal development. Journal of Clinical Immunology, 7, 81–97.
18. Holt, P. G., & Jones, C. A. (2000). The development of the immune system during pregnancy and early life. Allergy, 55, 688.
19. Vrecenak, J. D., & Flake, A. W. (2013). In utero hematopoietic cell transplantation-recent progress and the potential for clinical application. Cytotherapy, 15(5), 525–35. doi:10.1016/j.jcyt.2013.01.003.
20. Roybal, J. L., Laje, P., Vrecenak, J. D., & Flake, A. W. (2012). Use of manipulated stem cells for prenatal therapy. Methods in Molecular Biology, 891, 169–81.
21. Xie Z., Chang C., Zhou Z. (2014). Molecular mechanisms in autoimmune type 1 diabetes: a critical review. Clinical Reviews Allergy Immunology, 47(2), 174–92.
22. Shoenfeld, Y. and Gershwin, M.E. (2002). “Autoimmunity at a glance.”. Autoimmune Reviews 1: 1. doi:10.1016/S1568-9972(01)00011-8
23. Tatsuo Kawai, David H. Sachs, A. Benedict Cosimi. Clinical Transplantation Tolerance. In: Textbook of Organ Transplantation. John Wiley & Sons, Ltd, 2014:844–854.
24. Fuchs, E. J. (2014). Transplantation tolerance: from theory to clinic. Immunological Reviews, 258(1), 64–79.
25. Kawai, T., Sachs, D. H., Sprangers, B., Spitzer, T. R., Saidman, S. L., Zorn, E., Tolkoff-Rubin, N., Preffer, F., Crisalli, K., Gao, B., Wong, W., Morris, H., LoCascio, S. A., Sayre, P., Shonts, B., Williams, W. W., Smith, R.-N., Colvin, R. B., Sykes, M., & Cosimi, A. B. (2014). Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. American Journal of Transplantation, 14(7), 1599–1611.
26. Paul, L. C., & Tilney, N. L. (1996). Alloantigen-dependent events in chronic rejection. In N. L. Tilney, T. B. Strom, & L. C. Paul (Eds.), Transplantation biology: Cellular and molecular aspects (pp. 567–75). Philadelphia: Lippincott-Raven.
27. Tilney, N. L., & Paul, L. C. (1996). Antigen-independent events leading to chronic graft dysfunction. In N. L. Tilney, T. B. Strom, & L. C. Paul (Eds.), Transplantation biology: Cellular and molecular aspects (pp. 629–37). Philadelphia: Lippincott-Raven.
28. Krensky, A. M., Weiss, A., Crabtree, G., Davis, M. M., & Parham, P. (1990). T-lympho- cyte–antigen interactions in transplant rejection. New England Journal of Medicine, 322, 510–7.
29. Zantvoort F. A., D'Amaro J., Persijn G. G., et al. (1996). “The impact of HLA-A matching on long-term survival of renal allografts,”. Transplantation, 61(5), 841–844.
30. Takemoto S. K., Terasaki P. I., Gjertson D. W., Cecka J. M. (2000). “Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation,” The New England Journal of Medicine, 343(15), 1078–1084.
31. Colvin, R. B., & Smith, R. N. (2005). Antibody-mediated organ-allograft rejection. Nature Reviews Immunology, 5(10), 807–817.
32. Janeway C. A. Jr., Travers P., Walport M., et al. (2001). Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; Responses to alloantigens and transplant rejection. Available from: http://www.ncbi.nlm.nih.gov/books/NBK27163/.
33. Trowsdale, J., & Betz, A. G. (2006). Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nature Immunology, 7(3), 241–246. doi:10.1038/ni1317.
34. Welniak, L. A., Blazar, B. R., & Murphy, W. J. (2007). Immunobiology of allogeneic hematopoietic stem cell transplantation. Annual Review of Immunology, 25, 139–170.
35. Jagasia, M., Arora, M., Flowers, M. E., et al. (2012). Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 119, 296–307.
36. http://bethematch.org/For-Patients-and-Families/Finding-a-donor/HLA-matching/
37. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987). The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature, 329, 512–518.
38. Beck S., Trowsdale J., (2000). The human major histocompatibility complex: lessons from the DNA sequence. Annu Rev Genomics Hum Genet;1:117–137. http://www-immuno.path.cam.ac.uk/~immuno/mhc/mhc.html.
39. Lee, S. J., Klein, J., Haagenson, M., et al. (2007). High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood, 110, 4576–4583.
40. Nandita, K., Zeliadt, S. B., & Stephanie, J. (2012). Economics of hematopoietic cell transplantation. Blood, 120(8), 1545–1551. doi:10.1182/blood-2012-05-426783G.
41. Opelz, & D¨ohler, B. (2007). Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation, 84(2), 137–143.
42. Starzl, T. E., Demetris, A. J., Murase, N., Thomson, A. W., Trucco, M., & Ricordi, C. (1993). Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunology Today, 14(6), 326–332.
43. Zhao, T., Zhang, Z. N., Rong, Z., & Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474, 212–215.
44. Tang, C., & Drukker, M. (2011). Potential barriers to therapeutic sutilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations. Seminars in Immunopathology, 33, 563–572.
45. Martin, M. J., Muotri, A., Gage, F., & Varki, A. (2005). Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nature Medicine, 11, 228–232.
46. Araki, R., Uda, M., Hoki, Y., Sunayama, M., Nakamura, M., Ando, S., Sugiura, M., Ideno, H., Shimada, A., Nifuji, A., & Abe, M. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 49(4), 100–104.
47. Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 12, 407–412.
48. Morizane, A., Doi, D., Kikuchi, T., Okita, K., Hotta, A., Kawasaki, T., Hayashi, T., Onoe, H., Shiina, T., Yamanaka, S., & Takahashi, J. (2013). Direct comparison of autologous and allogeneic transplantation of iPSC- derived neural cells in the brain of a nonhuman primate. Stem Cell Reports, 1, 283–292.
49. Fairchild, P. J., Cartland, S., Nolan, K. F., & Waldmann, H. (2004). Embryonic stem cells and the challenge of transplantation tolerance. Trends in Immunology, 25, 465–470.
50. Robertson, N. J., Brook, F. A., Gardner, R. L., Cobbold, S. P., Herman, W., & Fairchild, P. J. (2007). Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proceedings of the National Academy of Sciences of the United States of America, 104, 20920–20925.
51. Liu, P., Chen S., Li X., Qin L., Huang K., Wang L., et al. (2013). Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells. PLoS One 8(7):e69617. doi:10.1371/journal.pone.0069617.
52. Polo, J. M., Liu S., Figueroa M. E., Kulalert W., Eminli S., Tan K. Y., et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology, 28(8), 848–55.
53. Gimsa, U., Mitchison N. A., and Brunner-Weinzierl C. (2013). Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-Cell-mediated neuroinflammation. Mediators of Inflammation Vol 2013, Article ID 320519, 11 pages.
54. Kurtzberg, J., Prasad, V. K., Carter, S. L., et al. (2008). Results of the cord blood transplantation study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood, 112(10), 4318–4327.
55. Kamani, N., Spellman, S., Hurley, C. K., Barker, J. N., Smith, F. O., Oudshoorn, M., Bray, R., Smith, A., Williams, T. M., Logan, B., Eapen, M., Anasetti, C., Setterholm, M., Confer, D. L., & National Marrow Donor Program. (2008). State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biology of Blood and Marrow Transplantation, 14(1), 1–6.
56. Torikai, H. 1., Reik A., Soldner F., Warren E. H., Yuen C., Zhou Y., et al. (2013). Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood, 122(8), 1341–9.
57. Roca, V., Casabona J. C., Radice P., Murta V., Pitossi F. J. (2011). The degenerating substantia nigra as a susceptible region for gene transfermediated inflammation. Parkinsons Dis 2011:931572.
58. Date, I., Kawamura, K., & Nakashima, H. (1988). Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. Experimental Brain Research, 73, 15–22.
59. Tambur, A. R. (2004). Transplantation immunology and the central nervous system. Neurological Research, 26, 243–55.
60. Date, I., Felten, S. Y., & Felten, D. L. (1991). The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft. Brain Research, 545, 191–8.
61. Muldoon, et al. (2013). Immunologic privilege in the central nervous system and the blood–brain barrier. Journal of Cerebral Blood Flow and Metabolism, 33(1), 13–21.
62. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815–22.
63. Figliuzzi, M., Cornolti, R., Perico, N., et al. (2009). Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplantation Proceedings, 41, 1797–800.
64. Li, H., Guo, Z., Jiang, X., Zhu, H., Li, X., & Mao, N. (2008). Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells, 26, 2531–41.
65. F. Nakajima, K. Tokunaga, and N. Nakatsuji, “Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy,” Stem Cells, vol. 25, no. 4, pp. 983– 985, 2007.
66. Barker, R. A., Barrett, J., Mason, S. L., Björklund, A. (2013). Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurological 12, 84–91.
67. Mathieu, P., Battista, D., Depino, A., Valeria Roca y Fernando J. Pitossi. (2010). The more you have, the less you get: the functional role of inflammation on neuronal differentiation of endogenous and transplanted neural stem cells in the adult brain. Journal of Neurochemistry, 112(6), 1368–85.
68. Pott-Godoy, C., Tarelli, R., Ferrari, C., Sarchi, M. I., Pitossi, F. (2008). Central and systemic Interleukin-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson ‘s disease. Brain, 131(Pt 7), 1880–94.
69. Taylor, C. J., Bolton, E. M., Pocock, S., Sharples, L. D., Pedersen, R. A., & Bradley, J. A. (2005). Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. The Lancet, 366, 2019–2025.
70. Kollman, C., Maiers, M., Gragert, L., et al. (2007). Estimation of HLA- A, −B, −DRB1 haplotype frequencies using mixed resolution data from a national registry with selective retyping of volunteers. Human Immunology, 68(12), 950–958.
71. Zimmermann, A., Preynat-Seauve, O., Tiercy, J., Krause, K., & Villard, J. (2012). Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells and Development, 21(13), 2364–2373.
72. Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012). Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell, 11, 147–152.
73. Nakatsuji, N., Nakajima, F., & Tokunaga, K. (2008). HLA-haplotype banking and iPS cells. Nature Biotechnology, 26, 739–740.
74. Gourraud, P. A., Gilson, L., Girard, M., & Peschanski, M. (2012). The role of human leukocyte antigen matching in the development of multiethnic “haplobank” of induced pluripotent stem cell lines. Stem Cells, 30, 180–186.
75. Klitz, W., Gragert, L., Maiers, M., et al. (2009). Four-locus high-resolution HLA typing in a sample of Mexican Americans. Tissue Antigens, 74(6), 508–513.
76. http://www.bmdw.org/uploads/media/BMDW2011.pdf
77. Carvalho, M. G., Tsuneto, L. T., Moita Neto, J. M., Sousa, L. C., Sales Filho, H. L., Macêdo, M. B., Barroso, J. R., Pereira, E. M., Araújo, A. S., Silva, A. S., & Monte, S. J. (2013). HLA-A, HLA-B and HLA-DRB1 haplotype frequencies in Piauí’s volunteer bone marrow donors enrolled at the Brazilian registry. Human Immunology, 74(12), 1598–602. doi:10.1016/j.humimm.2013.08.283.
78. Chhaya, S. U., & Shankarkumar, U. (2003). HLA Antigen distribution in selected Gujarati subcaste from Mumbai, Maharastra, India. International Journal of Human Genetics, 3(3), 135–138.
79. Qinqin Pan, S., Fan, X. W., Zhao, X., Pan, M., Wang, C., & Shen, J. (2011). The distribution of HLA-A, −B, and -DRB1 alleles and haplotypes in inhabitants of Guizhou Province of China. Journal Biomedicine Research, 25(5), 328–334. doi:10.1016/S1674-8301(11)60044-4.
80. Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013). Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell, 13(4), 382–4. doi:10.1016/j.stem.2013.08.003.
81. Andrews, P. W., Joy, C., Robert, D., Ellen, F., Ed, H., Armand, K., Mahendra, R., Marc, T., Ian, W., & Shinya, Y. (2014). Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nature Biotechnology, 32, 724–726.
82. Chidgey, P., Layton, D., Trounson, A., & Boyd, R. L. (2008). Tolerance strategies for stem-cell-based therapies. Nature, 453(7193), 330–337.
83. Fairchild, P. J. (2010). The challenge of immunogenicity in the questfor induced pluripotency. Nature Reviews Immunology, 10(12), 868–875.
84. Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., Munn, D. H., Mellor, A. L., Karlsson, M. C., & McGaha, T. L. (2012). Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proceedings of the National academy of Sciences of the United States of America, 109, 3909–3914.
85. Swijnenburg, R. J., Schrepfer, S., Govaert, J. A., Cao, F., Ransohoff, K., Sheikh, A. Y., Haddad, M., Connolly, A. J., Davis, M. M., Robbins, R. C., & Wu, J. C. (2008). Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proceedings of the National academy of Sciences of the United States of America, 105, 12991–12996.
86. Pearl, J. I., Lee, A. S., Leveson-Gower, D. B., Sun, N., Ghosh, Z., Lan, F., Ransohoff, J., Negrin, R. S., Davis, M. M., & Wu, J. C. (2011). Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell, 8, 309–317.
87. Dhodapkar, M. V., & Steinman, R. M. (2002). Antigen-bearing immature dendritic cells induce peptide-specific CD8 regulatory T cells in vivo in humans. Blood, 100, 174–177.
88. Anderson, G., Lane, P. J., & Jenkinson, E. J. (2007). Generating intrathy-microenvironments to establish T-cell tolerance. Nature Reviews Immunology, 7, 954–963.
89. Parent, A. V., Russ, H. A., Khan, I. S., LaFlam, T. N., Metzger, T. C., Anderson, M. S., & Hebrok, M. (2013). Generation of functional thymic epithelium from human embryonic stem cells that supports host T cell development. Cell Stem Cell, 13, 219–229.
90. Sun, X., Xu, J., Lu, H., Liu, W., Miao, Z., Sui, X., Liu, H., Su, L., Du, W., He, Q., Chen, F., Shi, Y., & Deng, H. (2013). Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-like cells reconstitutes the thymic microenvironment in vivo. Cell Stem Cell, 13, 230–236.
91. Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity, 24, 233–238.
92. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., & Honjo, T. (2000). Engagement of the PD-1 immunoin-hibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Journal of Experimental Medicine, 192, 1027–1034.
93. Chen, T.-C., Waldmann, H., & Fairchild, P. J. (2004). Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen, Dby. Journal of Clinical Investigation, 113, 1754–1762.
94. Scott, D., Addey, C., Ellis, P., et al. (2000). Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity, 12, 711–720.
95. Riolobos, L., Hirata, R. K., Turtle, C. J., Pei-Rong, W., Gornalusse, G. G., Maja, Z., Riddell, S. R., & Russell, D. W. (2013). HLA Engineering of Human Pluripotent Stem Cells Molecular Therapy, 21(6), 1232–1241. doi:10.1038/mt.2013.59.